Unknown

Dataset Information

0

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.


ABSTRACT:

Introduction

CKLF like MARVEL transmembrane domain containing 6 (CMTM6) has been described as a programmed death ligand 1 (PD-L1) regulator at the protein level by modulating stability through ubiquitination. In this study, we describe the patterns of CMTM6 expression and assess its association with response to programmed cell death 1 pathway blockade in NSCLC.

Methods

We used multiplexed quantitative immunofluorescence to determine the expression of CMTM6 and PD-L1 in 438 NSCLCs represented in tissue microarrays, including in two independent retrospective cohorts of immunotherapy-treated (n = 69) and non-immunotherapy-treated (n = 258) patients and a third collection of EGFR- and KRAS-genotyped tumors (n = 111).

Results

Tumor and stromal CMTM6 expression was detected in approximately 70% of NSCLCs. CMTM6 expression was not associated with clinical features or EGFR/KRAS mutational status and showed a modest correlation with T-cell infiltration (R2 < 0.40). We found a significant correlation between CMTM6 and PD-L1, which was higher in the stroma (R2 = 0.51) than in tumor cells (R2 = 0.35). In our retrospective NSCLC cohort, neither CMTM6 nor PD-L1 expression alone significantly predicted immunotherapy outcomes. However, high CMTM6 and PD-L1 coexpression in the stromal and CD68 compartments (adjusted hazard ratio = 0.38, p = 0.03), but not in tumor cells (p = 0.15), was significantly associated with longer overall survival in treated patients but was not observed in the absence of immunotherapy.

Conclusion

This study supports the mechanistic role for CMTM6 in stabilization of PD-L1 in patient tumors and suggests that high coexpression of CMTM6 and PD-L1, particularly in stromal immune cells (macrophages), might identify the greatest benefit from programmed cell death 1 axis blockade in NSCLC.

SUBMITTER: Zugazagoitia J 

PROVIDER: S-EPMC6951804 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.

Zugazagoitia Jon J   Liu Yuting Y   Toki Maria M   McGuire John J   Ahmed Fahad Shabbir FS   Henick Brian S BS   Gupta Richa R   Gettinger Scott N SN   Herbst Roy S RS   Schalper Kurt A KA   Rimm David L DL  

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20191009 12


<h4>Introduction</h4>CKLF like MARVEL transmembrane domain containing 6 (CMTM6) has been described as a programmed death ligand 1 (PD-L1) regulator at the protein level by modulating stability through ubiquitination. In this study, we describe the patterns of CMTM6 expression and assess its association with response to programmed cell death 1 pathway blockade in NSCLC.<h4>Methods</h4>We used multiplexed quantitative immunofluorescence to determine the expression of CMTM6 and PD-L1 in 438 NSCLCs  ...[more]

Similar Datasets

| S-EPMC10314861 | biostudies-literature
2025-03-31 | GSE291670 | GEO
| S-EPMC7351334 | biostudies-literature
| S-EPMC9356091 | biostudies-literature
| S-EPMC9310269 | biostudies-literature
| S-EPMC4292419 | biostudies-other
| S-EPMC10917783 | biostudies-literature
| S-EPMC7781756 | biostudies-literature
| S-EPMC4538573 | biostudies-literature
| S-EPMC7883863 | biostudies-literature